The Role of T-Regulatory Cells in the Immune System and Their Therapeutic Potential in Inflammation and Lung Cancer

Trends in Immunotherapy

Review

The Role of T-Regulatory Cells in the Immune System and Their Therapeutic Potential in Inflammation and Lung Cancer

Downloads

https://doi.org/10.54963/ti.v9i3.1201
Ivanovich, K. V. (2025). The Role of T-Regulatory Cells in the Immune System and Their Therapeutic Potential in Inflammation and Lung Cancer. Trends in Immunotherapy, 9(3), 183–196. https://doi.org/10.54963/ti.v9i3.1201
Volume 9 Issue 3 (September 2025) (in progress)
Copyright (c) 2025 Kobylyansky Viacheslav Ivanovich
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright

The authors shall retain the copyright of their work but allow the Publisher to publish, copy, distribute, and convey the work.

License

Trends in Immunotherapy (TI)  publishes accepted manuscripts under Creative Commons Attribution 4.0 International (CC BY 4.0). Authors who submit their papers for publication by TI agree to have the CC BY 4.0 license applied to their work, and that anyone is allowed to reuse the article or part of it free of charge for any purpose, including commercial use. As long as the author and original source are properly cited, anyone may copy, redistribute, reuse, and transform the content.

Authors

  • Kobylyansky Viacheslav Ivanovich

    Research Institute of the Federal Medical and Biological Agency of Russia, Orekhovy Boulevard 28, Moscow 115682, Russian Federation

Received: 16 April 2025; Revised: 14 May 2025; Accepted: 01 July 2025; Published: 2 September 2025

One of the key links of the immune system, which plays a crucial role in maintaining homeostasis and lung function, is T-regulatory cells (Treg). Their suppressive effect on the immune system predetermines the potential of various modulating effects, taking into account the pathogenetic features of the pathology, which underlie innovative methods of therapy, including in pulmonology. However, awareness of them remains insufficient and, in some cases, contradictory, which requires appropriate consideration and analysis, which became the purpose of this work. An analysis of 69 literary sources selected from different databases of biomedical scientific information was carried out. The analysis showed that targeted methods for the treatment of inflammation and tumors are developed based on the generally accepted paradigm about Treg and are aimed at their modulation. In inflammation, activation of Treg, exerting a suppressive effect on T-effector cells, reduces it. In tumors, their depletion, promoting the expression of T-effector cells, including antitumor cells, slows their growth. This is achieved by various direct or indirect methods of influence. Along with this, some researchers suggest using a depleting effect on Tregs in inflammation, and similarly, in both tumor and inflammatory processes, which contradicts the generally accepted paradigm regarding Tregs. Thus, a modulating effect on Tregs can have a therapeutic effect on both inflammation and tumors, with a differentiated consideration of the mechanisms of their development. Methods of treating inflammation that contradict the generally accepted paradigm regarding Tregs remain unsupported by a sufficient evidence base and are untenable.

Keywords:

T‑Regulatory Cells Adoptive Transfer IL‑2, Inflammation COVID‑19 Autoimmune Oncological Processes Cytostatics

References

  1. Ahmad, S.; Manzoor, S.; Siddiqui, S.; et al. Epigenetic Underpinnings of Inflammation: Connecting the Dots Between Pulmonary Diseases, Lung Cancer and COVID-19. Semin. Cancer Biol. 2022, 83, 384–398.
  2. Fuchs, A.; Gliwiński, M.; Grageda, N.; et al. Minimum Information About T Regulatory Cells: A Step Toward Reproducibility and Standardization. Front. Immunol. 2018, 8, 1844.
  3. Ito, H.; Seishima, M. Regulation of the Induction and Function of Cytotoxic T Lymphocytes by Natural Killer T Cell. J. Biomed. Biotechnol. 2010, 2010, 641757.
  4. Chen, S.; Saeed, A.F.U.H.; Liu, Q.; et al. Macrophages in Immunoregulation and Therapeutics. Signal Transduct. Target Ther. 2023, 8, 207.
  5. Zhang, Y.S.; Chen, Y.Q. Dysfunctional Regulatory T Cell: May Be an Obstacle to Immunotherapy in Cardiovascular Diseases. Biomed. Pharmacother. 2024, 173, 116359.
  6. Rajendeeran, A.; Tenbrock, K. Regulatory T Cell Function in Autoimmune Disease. J. Transl. Autoimmun. 2020, 4, 100130.
  7. Mock, J.R.; Dial, C.F.; Tune, M.K.; et al. Impact of Regulatory T Cells on Type 2 Alveolar Epithelial Cell Transcriptomes During Resolution of Acute Lung Injury and Contributions of IFN-γ. Am. J. Respir. Cell Mol. Biol. 2020, 63, 464–477.
  8. Liang, J.; Bi, G.; Shan, G.; et al. Tumor-Associated Regulatory T Cells in Non-Small-Cell Lung Cancer: Current Advances and Future Perspectives. J. Immunol. Res. 2022, 2022, 4355386.
  9. Principe, D.R.; Chiec, L.; Mohindra, N.A.; et al. Regulatory T-Cells as an Emerging Barrier to Immune Checkpoint Inhibition in Lung Cancer. Front. Oncol. 2021, 11, 684098.
  10. Wang, H.; Wang, Z.; Cao, W.; et al. Regulatory T Cells in COVID-19. Aging Dis. 2021, 12, 1545–1553.
  11. Xu, Z.; Jiang, X.; Dai, X.; et al. The Dynamic Role of FOXP3+ Tregs and Their Potential Therapeutic Applications During SARS-CoV-2 Infection. Front. Immunol. 2022, 13, 916411.
  12. Zhang, R.; Zhao, Y.; Chen, X.; et al. Low-Dose IL-2 Therapy in Autoimmune Diseases: An Update Review. Int. Rev. Immunol. 2024, 43, 113–137.
  13. Allegretti, J.R.; Mitsialis, V.; Canavan, J.B.; et al. Low-Dose Interleukin 2 for the Treatment of Moderate to Severe Ulcerative Colitis. Gastroenterology 2023, 165, 492–495.
  14. Hoyer, K.K.; Dooms, H.; Barron, L.; et al. Interleukin-2 in the Development and Control of Inflammatory Disease. Immunol. Rev. 2008, 226, 19–28.
  15. Yu, A.; Snowhite, I.; Vendrame, F.; et al. Selective IL-2 Responsiveness of Regulatory T Cells Through Multiple Intrinsic Mechanisms Supports the Use of Low-Dose IL-2 Therapy in Type 1 Diabetes. Diabetes 2015, 64, 2172–2183.
  16. Veiga-Parga, T.; Sehrawat, S.; Rouse, B.T. Role of Regulatory T Cells During Virus Infection. Immunol. Rev. 2013, 255, 182–196.
  17. Wang, F.; Hou, H.; Luo, Y.; et al. The Laboratory Tests and Immunity of COVID-19 Patients With Different Severity of Illness. JCI Insight 2020, 5, e137799.
  18. Dicharry, D.; Malek, A.E. Unlocking the Role of Treg Cells Immune Response and Infectious Risk Following CAR T-Cell Therapy in Patients With Cancer. Int. J. Mol. Sci. 2025, 26, 1602.
  19. Li, J.; Chen, X.; Qu, Y. Effects of Cyclophosphamide Combined With Prednisone on TNF-α Expression in Treatment of Patients With Interstitial Lung Disease. Exp. Ther. Med. 2019, 18, 4443–4449.
  20. Pukhalsky, A.L.; Shmarina, G.V.; Aleshkin, V.A. Immunological Disorders and Cognitive Deficits During Stress and Physiological Aging. Part II: New Approaches to the Prevention and Treatment of Cognitive Disorders. Bull. Russ. Acad. Med. Sci. 2014, 30–37. (in Russian)
  21. Sinitsyn, E.A.; Zykova, A.A.; Shamin, R.V.; et al. Efficacy and Safety of Ultra-Low-Dose Inhaled Melphalan in the Treatment of Hospitalized Patients With COVID-19. Acta Biomed. Sci. 2022, 7, 12–23. (in Russian)
  22. Shmarina, G.; Pukhalsky, A.; Alioshkin, V.; et al. Melphalan Reduces the Severity of Experimental Colitis in Mice by Blocking Tumor Necrosis Factor-Alpha Signaling Pathway. Ann. N. Y. Acad. Sci. 2007, 1096, 97–105.
  23. Pukhalsky, A.; Shmarina, G.; Alioshkin, V.; et al. Alkylating Drugs Applied in Non-Cytotoxic Doses as Novel Compounds Targeting Inflammatory Signal Pathway. Biochem. Pharmacol. 2006, 72, 1432–1438.
  24. Fan, M.Y.; Low, J.S.; Tanimine, N.; et al. Differential Roles of IL-2 Signaling in Developing Versus Mature Tregs. Cell Rep. 2018, 25, 1204–1213.
  25. Raeber, M.E.; Sahin, D.; Karakus, U.; et al. A Systematic Review of Interleukin-2-Based Immunotherapies in Clinical Trials for Cancer and Autoimmune Diseases. EBioMedicine 2023, 90, 104539.
  26. Zhang, J.; Huang, Y. Low-Dose IL-2 in the Treatment of Immune-Related Diseases. Eur. J. Inflamm. 2021, 19, 20587392211039935.
  27. Amini, L.; Kaeda, J.; Weber, O.; et al. Low-Dose Interleukin-2 Therapy: Fine-Tuning Treg in Solid Organ Transplantation? Transplantation 2024, 23, 0000000000004866.
  28. Ghelani, A.; Bates, D.; Conner, K.; et al. Defining the Threshold IL-2 Signal Required for Induction of Selective Treg Cell Responses Using Engineered IL-2 Muteins. Front. Immunol. 2020, 11, 1106.
  29. Kobylyansky, V.I. Assessing the Effectiveness of Inhaled Immunosuppressive Drugs in the Treatment of COVID-19. Infect. Dis. News Opin. Train. 2023, 12, 81–89. (in Russian)
  30. Lutsiak, M.E.; Semnani, R.T.; De Pascalis, R.; et al. Inhibition of CD4⁺25⁺ T Regulatory Cell Function Implicated in Enhanced Immune Response by Low-Dose Cyclophosphamide. Blood 2005, 105, 2862–2868.
  31. Su, Y.C.; Rolph, M.S.; Cooley, M.A.; et al. Cyclophosphamide Augments Inflammation by Reducing Immunosuppression in a Mouse Model of Allergic Airway Disease. J. Allergy Clin. Immunol. 2006, 117, 635–641.
  32. Flores, C.; Fouquet, G.; Cruz Moura, I.; et al. Lessons to Learn From Low-Dose Cyclosporin-A: A New Approach for Unexpected Clinical Applications. Front. Immunol. 2019, 10, 588.
  33. Loeffler, M.; Krüger, J.A.; Reisfeld, R.A. Immunostimulatory Effects of Low-Dose Cyclophosphamide Are Controlled by Inducible Nitric Oxide Synthase. Cancer Res. 2005, 65, 5027–5030.
  34. Becker, J.C.; Schrama, D. The Dark Side of Cyclophosphamide: Cyclophosphamide-Mediated Ablation of Regulatory T Cells. J. Invest. Dermatol. 2013, 133, 1462–1465.
  35. Scurr, M.; Pembroke, T.; Bloom, A.; et al. Low-Dose Cyclophosphamide Induces Antitumor T-Cell Responses, Which Associate With Survival in Metastatic Colorectal Cancer. Clin. Cancer Res. 2017, 23, 6771–6780.
  36. Heylmann, D.; Bauer, M.; Becker, H.; et al. Human CD4⁺CD25⁺ Regulatory T Cells Are Sensitive to Low-Dose Cyclophosphamide: Implications for the Immune Response. PLoS One 2013, 8, e83384.
  37. Peng, K.; Li, X.; Yang, D.; et al. Risk of Autoimmune Diseases Following COVID-19 and the Potential Protective Effect From Vaccination: A Population-Based Cohort Study. EClinicalMedicine 2023, 63, 102154.
  38. Sharma, C.; Bayry, J. High Risk of Autoimmune Diseases After COVID-19. Nat. Rev. Rheumatol. 2023, 19, 399–400.
  39. Caraffa, A.; Gallenga, C.E.; Kritas, S.K.; et al. CAR-T Cell Therapy Causes Inflammation by IL-1 Which Activates Inflammatory Cytokine Mast Cells: Anti-Inflammatory Role of IL-37. J. Biol. Regul. Homeost. Agents 2019, 33, 1981–1985.
  40. Kuczma, M.; Ding, Z.C.; Zhou, G. Immunostimulatory Effects of Melphalan and Usefulness in Adoptive Cell Therapy With Antitumor CD4⁺ T Cells. Crit. Rev. Immunol. 2016, 36, 179–191.
  41. Revannasiddaiah, S.; Devadas, S.K.; Palassery, R.; et al. A Potential Role for Cyclophosphamide in the Mitigation of Acute Respiratory Distress Syndrome Among Patients With SARS-CoV-2. Med. Hypotheses 2020, 144, 109850.
  42. Kobylyansky, V.I. Possibilities of Using Immunosuppressants and Their Aerosol Delivery to the Lungs in the Treatment of Severe Bronchial Asthma. Clin. Pharmacol. Ther. 2022, 31, 14–19. (in Russian)
  43. Tyulyandin, S.A.; Samoilenko, I.V.; Izmerova, N.I. Guidance for Medical Personnel on the Safe Handling of Anticancer Drugs; Research Institute of Occupational Medicine RAS: Moscow, Russia, 2012.
  44. Zeng, G.; Jin, L.; Ying, Q.; et al. Regulatory T Cells in Cancer Immunotherapy: Basic Research Outcomes and Clinical Directions. Cancer Manag. Res. 2020, 12, 10411–10421.
  45. Tanaka, A.; Sakaguchi, S. Regulatory T Cells in Cancer Immunotherapy. Cell Res. 2017, 27, 109–118.
  46. Kotton, D.N.; Morrisey, E.E. Lung Regeneration: Mechanisms, Applications and Emerging Stem Cell Populations. Nat. Med. 2014, 20, 822–832.
  47. Kohler, D. Aerosols for Systemic Treatment. Lung 1990, 168, 677–668.
  48. Lai, S.; Hard, D.M.; Bhalla, K.K.; et al. Comparison of Beclometasone Dipropionate Aerosol and Prednisolon in Reversible Airways Obstruction. Br. Med. J. 1972, 3, 314–320.
  49. Plit, M.; Goldman, H.I.; Cassel, M.L.; et al. The Bronchodilator Action of Fenoterol (Berotec) in Asthma. Med. Proc. 1972, 18, 4.
  50. Kobylyansky, V.I. Mucociliary System; Fundamental and Applied Aspects; BINOM: Moscow, Russia, 2008. (in Russian)
  51. Fukava, H.; Limura, A.; Hoshiko, K.; et al. A Cyclosporin A/Maltosyl-α-Cyclodextrin Complex for Inhalation Therapy of Asthma. Eur. Respir. J. 2003, 22, 213–219.
  52. Yuan, Y.; Che, X.; Zhao, M. Development of Cyclosporine A Microemulsion for Parenteral Delivery. J. Microencapsul. 2015, 32, 273–280.
  53. European Patent Office. Cyclosporine Formulations for Use in the Prevention or Treatment of Pulmonary Chronic Graft Rejection. Eur. Pat. Appl. EP 3069711A1, 15 March 2015.
  54. Bustamante-Marin, X.M.; Ostrowski, L.E. Cilia and Mucociliary Clearance. Cold Spring Harb. Perspect. Biol. 2017, 9, a028241.
  55. Trammer, B.; Amann, A.; Haltner-Ukomadu, E.; et al. Comparative Permeability and Diffusion Kinetics of Cyclosporine A Liposomes and Propylene Glycol Solution From Human Lung Tissue Into Human Blood ex Vivo. Eur. J. Pharm. Biopharm. 2008, 70, 758–764.
  56. Ahmad, J.; Akhter, S.; Rizwanullah, M.; et al. Nanotechnology-Based Inhalation Treatments for Lung Cancer: State of the Art. Nanotechnol. Sci. Appl. 2015, 8, 55–66.
  57. Labiris, N.R.; Dolovich, M.B. Pulmonary Drug Delivery. Part I: Physiological Factors Affecting Therapeutic Effectiveness of Aerosolized Medications. Br. J. Clin. Pharmacol. 2003, 56, 588–599.
  58. Labiris, N.R.; Dolovich, M.B. Pulmonary Drug Delivery. Part II: The Role of Inhalant Delivery Devices and Drug Formulations in Therapeutic Effectiveness of Aerosolized Medications. Br. J. Clin. Pharmacol. 2003, 56, 600–612.
  59. An, B.; Reinhardt, R.R. Effects of Different Durations of Breath Holding After Inhalation of Insulin Using the AERx Insulin Diabetes Management System. Clin. Ther. 2003, 25, 2233–2244.
  60. Ahookhosh, K.; Saidi, M.; Mohammadpourfard, M.; et al. Flow Structure and Particle Deposition Analyses for Optimization of a Pressurized Metered Dose Inhaler (pMDI) in a Model of Tracheobronchial Airway. Eur. J. Pharm. Sci. 2021, 164, 105911.
  61. Zykov, K.A. Method of Treatment of Patients with Bronchial Asthma [Bulletin No. 15; Issue No. 2356574]. 2008.
  62. Newman, S.P.; Clarke, S.W. Inhalation Devices and Techniques. In Asthma, Clark, T.J.H.; Godfrey, S.; Lee, T.H., Eds.; Chapman and Hall: London, UK, 1992; pp. 469–505.
  63. Tena, A.F.; Clarà, P.C. Deposition of Inhaled Particles in the Lungs. Arch. Bronconeumol. 2012, 48, 240–246.
  64. Chung, K.F.; Jeyasingh, K.; Snashall, P.D. Influence of Airway Calibre on the Intrapulmonary Dose and Distribution of Inhaled Aerosol in Normal and Asthmatic Subjects. Eur. Respir. J. 1988, 1, 890–895.
  65. Heyder, J. Mechanisms of Aerosol Particle Deposition. Chest 1980, 80, 820–824.
  66. Morgan, W.K.C.; Ahmad, D.; Chamberlain, M.Y.; et al. The Effect of Exercise on an Inhaled Aerosol. Respir. Physiol. 1984, 56, 327–338.
  67. Kobilyansky, V.I.; Artyushkin, A.V. USSR Author's Certificate for Invention No. 1524904. 1989. (in Russian)
  68. Breslav, I.S. Breathing Patterns; Nauka: Leningrad, Russia, 1984. (in Russian)
  69. Zhang, S.; Gang, X.; Yang, S.; et al. The Alterations in and the Role of the Th17/Treg Balance in Metabolic Diseases. Front. Immunol. 2021, 12, 678355.